At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.

The UK government has outlined its vision for creating a “world-leading, dynamic system of medicines regulation” once the UK fully leaves the EU at the end of the Brexit transition period on 31 December.

Among the aspirations are more streamlined… Read more »